louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03511950: The Relationship Between the Change of Resting Energy Expenditure and Nutritional Status .
Official title: The Relationship Between the Change of Resting Energy Expenditure(REE) and Nutritional Status in Peritoneal Dialysis(PD) Patients With Peritonitis.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Peritonitis
Resting Energy Expenditure
Nutrition
Lead sponsor: Peking University First Hospital
Sponsor class: OTHER
First posted: 2018-04-30
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: PD patients with confirm diagnosis of peritonitis

Brief summary: Peritonitis is a common and devastating complication in patients on peritoneal dialysis (PD). It is a known fact that persistent inflammatory state and nutritional deterioration are closely associated with increased mortality in PD patients.And resting energy expenditure(REE) is significantly increased in acute and chronic inflammation in patients with chronic kidney disease (including dialysis patients).However,it is limited to the changing trend and duration of REE in peritonitis.Investigators hypothesize that the increase in total energy consumption resulting from the increase of REE which may accompany with decreased energy intake will lead to negative energy balance and nutritional deterioration, which may affect the prognosis of patients.Therefore,a prospective cohort study will be designed to dynamically research the change of REE accompanied with the nutrition status in peritonitis and provide the basis for peritonitis management in the future.


Eligibility criteria: Inclusion Criteria:

* Receiving PD for\>3 months
* Age between 18 and 80 years
* Confirm diagnosis of peritonitis

Exclusion Criteria:

* Disability
* Other acute complications: including systemic infections except for peritonitis, acute cardia-cerebrovascular disease in one month
* Active hepatitis and musculoskeletal diseases in the past
* Cancer and is treated with chemoradiotherapy within 1 year
* Severe edema of the whole body or a large amount of body cavity effusion
* Thyroid dysfunction
* History of hormonal drugs use
* During pregnancy or lactation
* Mental disorder

Primary outcomes:
measure: The relationship between the change of REE and the change of albumin
timeFrame: 90 days
Secondary outcomes:
measure: The relationship between the change of REE and the change of BMI
timeFrame: 90 days
measure: The relationship between the change of REE and the change of handgrip strength
timeFrame: 90 days
measure: The relationship between the change of REE and the change of Fat mass
timeFrame: 90 days
measure: The relationship between the change of REE and the change of lean body mass
timeFrame: 90 days
Other outcomes:
measure: The relationship between the change of REE and the outcome of patients
timeFrame: 90 days or 180days
Locations:
city: Beijing
country: China
facility: Peking University First Hospital
Study officials:
References:
Clinical trial NCT01589250: Risk Scoring Systems in Upper GI-haemorrhage
Official title: Risk Scoring Systems in Upper GI-haemorrhage
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Upper Gastrointestinal Hemorrhage
Lead sponsor: Odense University Hospital
Sponsor class: OTHER
First posted: 2012-05-01
Enrollment: 831
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Data were collected from consecutive patients admitted with UGIH at Odense University Hospital between August 2009 and August 2011. UGIH was defined as history of haematemesis, coffee-ground vomit, or melaena.

Brief summary: Use of risk scoring systems in the assessment of patients presenting with upper gastrointestinal haemorrhage is increasing. Comparative studies have intended to identify the system of choice, but the majority of these are characterized by retrospective designs, small sample sizes, low rate of severe bleeding, or low mortality. The main aim of this study was to identify the optimal scoring system.


Eligibility criteria: Inclusion Criteria:

One of the following:

* Haematemesis
* Melaena
* Coffee-ground vomit

Primary outcomes:
measure: Need for hospital-based intervention
timeFrame: 1 month
Secondary outcomes:
measure: Identification of low-risk patients
timeFrame: 1 month
measure: Rebleeding
timeFrame: 1 month
measure: 30 day mortality
timeFrame: 30 days
Other outcomes:
Locations:
city: Odense
country: Denmark
facility: Odense University Hospital
Study officials:
References:
citation: Laursen SB, Hansen JM, Schaffalitzky de Muckadell OB. The Glasgow Blatchford score is the most accurate assessment of patients with upper gastrointestinal hemorrhage. Clin Gastroenterol Hepatol. 2012 Oct;10(10):1130-1135.e1. doi: 10.1016/j.cgh.2012.06.022. Epub 2012 Jul 16.
Clinical trial NCT01993550: Telephone Support Program for Lung Cancer Patients and Their Family Caregivers
Official title: Telephone Symptom Management for Advanced Lung Cancer Patients and Caregivers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lung Cancer
Keywords: lung cancer
family caregiving
behavioral intervention
counseling
symptom management
Lead sponsor: Indiana University
Sponsor class: OTHER
Collaborators: name: Indiana University School of Medicine
name: American Cancer Society, Inc.
name: National Cancer Institute (NCI)
First posted: 2013-11-25
Enrollment: 262
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The goal of this project is to examine the physical and psychological health benefits of a novel, telephone-delivered symptom management intervention for advanced lung cancer patients and their family caregivers.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of lung cancer
* Must be able to speak and read English

Exclusion Criteria:

* No working phone service
* Does not have a family caregiver

Primary outcomes:
measure: Change in Patient Health Questionnaire-8
timeFrame: baseline, 2 and 6 weeks post-intervention
measure: Change in Generalized Anxiety Disorder 7-item scale
timeFrame: baseline, 2 and 6 weeks post-intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Indianapolis
country: United States
facility: Eskenazi Hospital
state: Indiana
city: Indianapolis
country: United States
facility: Indiana University Simon Cancer Center
state: Indiana
city: Indianapolis
country: United States
facility: Richard L. Roudebush VA Medical Center
state: Indiana
Study officials:
affiliation: Indiana University School of Medicine
name: Catherine E. Mosher, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Winger JG, Rand KL, Hanna N, Jalal SI, Einhorn LH, Birdas TJ, Ceppa DP, Kesler KA, Champion VL, Mosher CE. Coping Skills Practice and Symptom Change: A Secondary Analysis of a Pilot Telephone Symptom Management Intervention for Lung Cancer Patients and Their Family Caregivers. J Pain Symptom Manage. 2018 May;55(5):1341-1349.e4. doi: 10.1016/j.jpainsymman.2018.01.005. Epub 2018 Jan 31.
Clinical trial NCT04540250: Stratification of Oral Ulcers in Rheumatoid Arthritis Patients Kept on Methotrexate
Official title: Stratification of Oral Lesions in Methotrexate-treated Rheumatoid Arthritis Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Methotrexate Adverse Reaction
Oral Mucositis
Lead sponsor: Beni-Suef University
Sponsor class: OTHER
First posted: 2020-09-07
Enrollment: 804
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: RA patients receiving MTX as monotherapy were included in the study. Patients suffering from systemic disease known to cause oral manifestations; salivary gland diseases and malignancies were excluded.

Brief summary: This study included rheumatoid arthritis patients receiving Methotrexate as monotherapy. All eligible patients were subjected to thorough clinical examination and full history to identify oral events. Drug history, current dose and duration of MTX were recorded.

Detailed description: The current study was conducted in the Clinics of Oral Medicine, Faculty of Dentistry and Rheumatology, Faculty of Medicine - Cairo University from 2017 to 2019. This study followed the principles of the Helsinki Declaration and was approved by the Research ethics committee of Faculty of Dentistry, Cairo University.

RA patients receiving MTX as monotherapy were included in the study. Patients suffering from systemic disease known to cause oral manifestations; salivary gland diseases and malignancies were excluded.

All eligible patients were subjected to thorough clinical examination for the whole oral cavity. Medical history and history of any oral manifestation were recorded. Drug history, dose, and duration of MTX were recorded.

Categorical data was presented as frequencies and percentages. Continuous data was described as means and standard deviations. Means were compared by one-way ANNOVA and Student-t-test. The significance level was set at P ≤0.05. Statistical analysis was performed with IBM® SPSS® Statistics Version 25 for Windows.

Eligibility criteria: Inclusion Criteria:

* patients with Rheumatoid arthritis using methotrexate as sole treatment

Exclusion Criteria:

* patients with Rheumatoid arthritis using any other treatments for Rheumatoid arthritis

Primary outcomes:
measure: occurrence of oral mucositis
timeFrame: throughout the study time (one year)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT07015008: Sleep and Maximal Fat Oxidation
Official title: Relationship Between Sleep Time and Maximal Fat Oxidation Capacity During Exercise.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sleep Deprivation
Lead sponsor: University of Alcala
Sponsor class: OTHER
First posted: 2025-06-11
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: Introduction: Despite the awareness of the importance of sleep in our lives, especially for athletes, the consequences of poor rest on sports performance are not well understood. Furthermore, the interaction between complete and partial sleep deprivation over one night and sleeping the usual hours for each person remains unclear.

Objectives: The aim of this study is to evaluate the effects of sleep deprivation on maximal fat oxidation (MFO) in male and female participants.


Eligibility criteria: Inclusion Criteria:

* Inclusion Criteria:

  * Age between 18 and 35 years.
  * Body Mass Index (BMI) \&lt; 25 kg/m².
  * Resistance-trained individuals (more than 2 years of structured training).
  * Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from exercising.
  * Participants must be able to perform the tests described in the following section.

Exclusion Criteria:

* History of neuromuscular diseases, heart disease, or conditions that may affect liver or muscle metabolism.
* Use of drugs, stimulants, or sports supplements that could interfere with the dietary supplement used in the study.
* Sedentary habits (less than 150 minutes/week of moderate exercise).
* Having undergone prolonged periods of physical inactivity in the 6 months prior to the study.
* Engaging in strenuous exercise within 48 hours prior to the tests.
* Failure to replicate the same food intake on both experimental days.
* Consumption of caffeine or any other stimulant the day before the tests.

Primary outcomes:
measure: Maximal Fat Oxidation Rate
timeFrame: Through study completion, an average of 4 weeks
Secondary outcomes:
measure: Fat mass
timeFrame: Through study completion, an average of 4 weeks
measure: Fat-free mass
timeFrame: Through study completion, an average of 4 weeks
Other outcomes:
Locations:
city: Alcalá de Henares
country: Spain
facility: Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá
state: Madrid
Study officials:
References:
Clinical trial NCT00370708: Early Oral Intake Following Cesarean Surgery
Official title: Early Oral Intake Following Elective Cesarean Surgery in Iranian Women; the Economic Burdens and Patient Satisfaction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obstetrics
Surgery
Keywords: Cesarean
Oral
Intake
Lead sponsor: Tehran University of Medical Sciences
Sponsor class: OTHER
First posted: 2006-09-01
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: In this study we are trying to compare the safety and financial benefit of starting the realimentation early versus conventional oral intake following the Cesarean surgery in Iran.

Detailed description: Cesarean delivery is announced to constitute 50% of deliveries in the Capital and 39% of all the deliveries nationwide, which is far beyond the acceptable international normal range, according to the official site of the Ministry of Health and Medical Education of the Islamic Republic of Iran \[http://www.mohme.gov.ir/HNDC/Indicators/Simaye_Salamt/Simaye_Salamat.htm\]. This high rate of elective cesarean deliveries might be due to several reasons which are far beyond the scope of this study. Here we tried to see whether the reduction in the time of hospitalization for these patients is safe at the expense of earlier oral realimentation and to see whether this strategy increases the patients' satisfaction or not.

Eligibility criteria: Inclusion Criteria:

Women who had elective cesarean deliveries under regional anesthesia

Exclusion Criteria:

1. Receiving general anesthesia, magnesium sulfate or insulin.
2. Coming across an intraoperative bowel injury.
3. Having any medical or gastrointestinal problem that prohibits early feeding

Primary outcomes:
measure: Tolerance of Oral Intake
Secondary outcomes:
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Department of Obstetrics and Gynecology, Arash Hospital
Study officials:
affiliation: Department of Obstetrics and Gynecology, Arash Hospital, Tehran University of Medical Sciences, Tehran/Iran
name: Afsaneh Tehranian, Assist Pro
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02012608: Glutamine for the Prevention of Radiation Toxicity in Subjects Conserving Therapy
Official title: Glutamine for the Prevention of Radiation Toxicity in Subjects Undergoing Breast Conserving Therapy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Breast Cancer
Keywords: breast
Lead sponsor: University of Arkansas
Sponsor class: OTHER
First posted: 2013-12-16
Enrollment: 14
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a single-centered, double-blind, two-arm randomized study to determine if oral glutamine will reduce radiation toxicity for the subjects undergoing Breast Conserving Therapy.


Eligibility criteria: Inclusion Criteria:

* Subject have been diagnosed with Stage I or II invasive breast cancer
* Subject will undergo Accelerated Partial Breast Irradiation (APBI) as part of Breast Conserving Therapy (BCT)
* Subject is eligible for APBI based on American Society of Therapeutic Radiation Oncology (ASTRO) criteria
* Subject is 18 years of age or older
* Subject is female

Exclusion Criteria:

* History of uncontrolled, clinically significant lung, heart, endocrine, liver, or renal disease
* Subject has been diagnosed with any other cancer
* Subject has a known hypersensitivity reaction to the following: oral glutamine (GLN), glutamate, monosodium glutamate (MSG) (i.e., Chinese restaurant syndrome)
* Subject has history of collagen vascular disease
* Subject has been diagnosed with Diabetes mellitus I or II
* Subject has had any prior breast radiation
* Subject is pregnant or breastfeeding

Primary outcomes:
measure: Excessive Radiation Toxicity as Defined by Radiation Therapy Oncology Group (RTOG) Acute Scale of Radiation-toxicity Criteria
timeFrame: 12 days and 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: University of Arkansas for Medical Sciences
state: Arkansas
Study officials:
affiliation: University of Arkansas
name: Loverd Peacock, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Arkansas
name: Yihong Kaufmann, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT06921408: Retrospective Identification of Scintigraphic Cardiac Amyloidosis (RISCA)
Official title: Retrospective Identification of Scintigraphic Cardiac Amyloidosis Using Deep Learning-based Model
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Cardiac Amyloidosis
Transthyretin Amyloidosis
Keywords: Cardiac Amyloidosis
Bone Scintigraphy
Deep learning
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
Collaborators: name: Pfizer
First posted: 2025-04-10
Enrollment: 57
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who underwent scintigraphy for reasons other than suspected amyloidosis

Brief summary: This study aims to determine the positive predictive value of incidental cardiac uptake on bone scintigraphy for diagnosing transthyretin cardiac amyloidosis, in patients who underwent scintigraphy for reasons other than suspected amyloidosis. The study is an observational, descriptive, multicenter, national study using retrospective data from routine care. Patients with incidental cardiac uptake will be recalled for further diagnostic assessment.


Eligibility criteria: Inclusion Criteria:

* Adults (≥ 18 years)
* Patients who underwent bone scintigraphy with 99mTc-HMDP/DPD/PYP for any indication
* Incidental cardiac uptake (Perugini grade ≥2) confirmed by a nuclear medicine specialist

Exclusion Criteria:

* Patients under legal protection
* Patients refusing the reuse of their data after individual information

Primary outcomes:
measure: Cardiac amyloidosis diagnosis
timeFrame: After the reassessment evaluation (one-day evaluation)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03631108: Feasibility Study and Preliminary Application Study on Iris OCTA
Official title: Feasibility Study and Preliminary Application Study on Noninvasive Iris Optical Coherence Tomography Angiography (OCTA)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Conjunctivitis
Glaucoma
Myopia
Diabetic Retinopathy
Retinal Detachment
Retinal Neovascularization, Unspecified
Uveitis
Keywords: Iris Vessel
OCTA
Lead sponsor: Shanghai Eye Disease Prevention and Treatment Center
Sponsor class: OTHER
First posted: 2018-08-15
Enrollment: 4000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Residents of Shanghai and patients from Shanghai Eye Hospital will be selected.

Brief summary: All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens. The main outcomes are iris blood flow density and vascular density.

Detailed description: 1. Feasibility study of iris OCTA technology
2. Establishment of iris OCTA database in normal population and analysis of related factors: (1) different sex; (2) different age; (3) different myopic diopter; (4) 24-hour diurnal changes from morning to night; (5) before and after mydriasis; (6) different blood pressure; (7) different intraocular pressure; (8) different blood glucose; (9) before and after exercise. (10) drinking water, tea, coffee and red wine.
3. Analysis of iris OCTA data related to eye diseases:(1) conjunctivitis; (2) glaucoma; (3) childhood myopia; (4) uveitis; (5) diabetic retinopathy; (6) retinal detachment; (7) fundus neovascularization.
4. Influence of commonly used ophthalmic drops on iris OCTA data. Observe the difference of iris OCTA test data before and after treatment: (1) conjunctivitis treated with levofloxacin antibiotics; (2) glaucoma treated with prostaglandins, adrenalines and receptor blockers; (3) childhood myopia treated with atropine drugs (4) uveitis treated with hormonal drugs. (5) diabetic retinopathy treated with vasodilator.
5. Effect on iris OCTA data before and after ophthalmic surgery. (1) cataract, phacoemulsification + intraocular lens implantation; (2) glaucoma, iridectomy; (3) fundus neovascularization, intraocular injection of anti-VEGF; (4) diabetic retinopathy, vitreous surgery.

Eligibility criteria: Inclusion Criteria:

* Healthy volunteers and ophthalmological patients who can understand and agree to cooperate this study will be included.

Exclusion Criteria:

* Patients who can not cooperate with the examination.

Primary outcomes:
measure: Iris Vessel Geometric Characteristics
timeFrame: 0:00 8:00 14:00 20:00
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Jia Y, Xue W, Tong X, Wang Y, Cui L, Zou H. Quantitative analysis and clinical application of iris circulation in ischemic retinal disease. BMC Ophthalmol. 2021 Nov 15;21(1):393. doi: 10.1186/s12886-021-02165-1.